Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial

MTN-025/HOPE was an open-label trial of the dapivirine vaginal ring conducted in four African countries between 2016 and 2018. Women were first offered one ring monthly (at baseline, months 1 and 2), thereafter, transitioned to a more applicable real-world dispensation schedule, − 3 rings quarterly...

Full description

Saved in:
Bibliographic Details
Published in:AIDS and behavior 2023-03, Vol.27 (3), p.1030-1043
Main Authors: Mirembe, Brenda Gati, Cabrera, Maria Valdez, van der Straten, Ariane, Nakalega, Rita, Cobbing, Mandy, Mgodi, Nyaradzo M., Palanee-Phillips, Thesla, Mayo, Ashley J., Dadabhai, Sufia, Mansoor, Leila E., Siva, Samantha, Nair, Gonasagrie, Chinula, Lameck, Akello, Carolyne A., Nakabiito, Clemensia, Soto-Torres, Lydia E., Baeten, Jared M., Brown, Elizabeth R.
Format: Article
Language:English
Subjects:
Acceptance
Acceptance tests
Adult
Africa
Anti-HIV Agents - therapeutic use
Birth control
Clinical trials
Contraception
Contraceptive Devices, Female
Disease prevention
Female
Health Psychology
HIV
HIV Infections - prevention & control
Human immunodeficiency virus
Humans
Infectious Diseases
Male
Medicine
Medicine & Public Health
Original Paper
Public Health
Pyrimidines - therapeutic use
Regression analysis
Sterilization
Vagina
Women
Womens health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MTN-025/HOPE was an open-label trial of the dapivirine vaginal ring conducted in four African countries between 2016 and 2018. Women were first offered one ring monthly (at baseline, months 1 and 2), thereafter, transitioned to a more applicable real-world dispensation schedule, − 3 rings quarterly (at months 3, 6 and 9). Logistic regression analysis was used to assess correlates of ring acceptance at baseline and through follow-up. A total of 1456 women (median age 31 years) enrolled, 1342 (92.2%) accepted the ring at baseline and 1163 (79.9%) accepted the ring(s) at all visits. Changing ring dispensation from a monthly to a quarterly schedule had no negative effect on acceptance. Having a primary partner and him knowing about the ring being offered in HOPE, use of long-acting contraception (implants, injections, IUDs) or sterilization were associated with ring acceptance, along with prior strong intention to use the ring in the future. Efforts should consider these factors when rolling out the ring for HIV prevention.
ISSN:1090-7165
1573-3254
1573-3254
DOI:10.1007/s10461-022-03841-z